[1] |
Fan Y, Qu X, Ma Y, et al. Cbl⁃b promotes cell detachment via ubiquitination of focal adhesion kinase[J]. Oncol Lett, 2016,12(2):1113⁃1118. doi: 10.3892/ol.2016.4730.
|
[2] |
Kang JM, Park S, Kim SJ, et al. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF⁃β signaling[J]. Oncogene, 2012,31(50):5123⁃5131. doi: 10.1038/onc.2012.18.
|
[3] |
王小坡, 温斯健, 粟倩雅, 等. 泛素连接酶Cbl⁃b在黑素瘤组织和细胞系A375、M14、MV3中的表达及意义[J]. 中华皮肤科杂志, 2016,49(12):861⁃864. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.12.007.
|
[4] |
王小坡, 倪娜娜, 熊竞舒, 等. 泛素连接酶Cbl⁃b基因短发卡RNA慢病毒载体构建及其对A375细胞生物学行为的影响[J]. 中华皮肤科杂志, 2018,51(3):177⁃181. doi: 10.3760/cma.j.issn.0412⁃4030.2018.03.003.
|
[5] |
Lento S, Brioschi M, Barcella S, et al. Proteomics of tissue factor silencing in cardiomyocytic cells reveals a new role for this coagulation factor in splicing machinery control[J]. J Proteomics, 2015,119:75⁃89. doi: 10.1016/j.jprot.2015.01.021.
|
[6] |
Chesor M, Roytrakul S, Graidist P, et al. Proteomics analysis of siRNA⁃mediated silencing of Wilms′ tumor 1 in the MDA⁃MB⁃468 breast cancer cell line[J]. Oncol Rep, 2014,31(4):1754⁃1760. doi: 10.3892/or.2014.3013.
|
[7] |
Harris HR, Bergkvist L, Wolk A. Folate intake and breast cancer mortality in a cohort of Swedish women[J]. Breast Cancer Res Treat, 2012,132(1):243⁃250. doi: 10.1007/s10549⁃011⁃1838⁃y.
|
[8] |
Mason JB, Tang SY. Folate status and colorectal cancer risk: a 2016 update[J]. Mol Aspects Med, 2017,53:73⁃79. doi: 10.1016/j.mam.2016.11.010.
|
[9] |
Zhang P, Bai H, Fu C, et al. RacGAP1⁃driven focal adhesion formation promotes melanoma transendothelial migration through mediating adherens junction disassembly[J]. Biochem Biophys Res Commun, 2015,459(1):1⁃9. doi: 10.1016/j.bbrc.2014.11.088.
|
[10] |
Kim JE, Finlay GJ, Baguley BC. The role of the hippo pathway in melanocytes and melanoma[J]. Front Oncol, 2013,3:123. doi: 10. 3389/fonc.2013.00123.
|
[11] |
Brown K, Yang P, Salvador D, et al. WNT/β⁃catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN⁃dependent manner[J]. Oncogene, 2017,36(22):3119⁃3136. doi: 10.1038/onc.2016.450.
|
[12] |
McQuade JL, Vashisht GY. Counteracting oxidative phosphory⁃lation⁃mediated resistance of melanomas to MAPK pathway inhibition[J]. Mol Cell Oncol, 2015,2(3):e991610. doi: 10.4161/23723556.2014.991610.
|
[13] |
Niessner H, Schmitz J, Tabatabai G, et al. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo[J]. Clin Cancer Res, 2016,22(23):5818⁃5828.doi: 10.1158/1078⁃0432.CCR⁃16⁃0064.
|
[14] |
Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond[J]. Nat Rev Cancer, 2010,10(3):165⁃180. doi: 10.1038/nrc2806.
|
[15] |
Paraiso KH, Das TM, Fang B, et al. Ligand⁃independent EPHA2 signaling drives the adoption of a targeted therapy⁃mediated metastatic melanoma phenotype[J]. Cancer Discov, 2015,5(3):264⁃273. doi: 10.1158/2159⁃8290.CD⁃14⁃0293.
|
[16] |
Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting[J]. Mol Cancer Res, 2008,6(12):1795⁃1806. doi: 10.1158/1541⁃7786.MCR⁃08⁃0244.
|